Cytiva says capacity investments and more localized production have improved supply chain security though its annual biomanufacturing landscape snapshot shows overall industry resilience is down. For the third year running, bioprocess vendor Cytiva has published results from its Biopharma Resilience Index, a survey of capabilities in five key areas rated by industry leaders. Among the reasons to be cheerful, over half the respondents (52%) believe it has become more affordable to manufacture drugs with the manufacturing agility score increasing compared…
